Cannabis

Sessions

Wednesday, 23 November

10:50

Commonalities across addictions

10:50 to 12:20

Insights zone 2 (I2)

Oral presentation session

Current and future challenges associated with emerging cannabis markets

10:50 to 12:20

Main stage

Structured session

Emerging changes in Europe's cannabis situation: policy preparedness and responses to a dynamic situation

10:50 to 12:20

Knowledge market 4 (K4)

Structured session

13:20

Assessing the impact of laws and policies regulating illicit drugs on health and society: some insights

13:20 to 14:50

Knowledge market 4 (K4)

Structured session

Cannabis

13:20 to 14:50

Networking zone 2 (N2)

e-poster guided tour

Global digital addiction interventions: adaptations to target audiences and effectiveness

13:20 to 14:50

Insights zone 2 (I2)

Structured session

Policies for regulating cannabis supply in Europe and the US: the need for appropriate monitoring and evaluation

13:20 to 14:50

Knowledge market 1 (K1)

Structured session

15:00

Spillover effects of drug policy and why better data are needed

15:00 to 16:30

Networking zone 1 (N1)

e-poster guided tour

Surveillance

15:00 to 16:30

Networking zone 4 (N4)

Short communication session

16:50

Driving under the influence of cannabis (DUIC)

16:50 to 18:20

Insights zone 3 (I3)

Structured session

Drugs and community

16:50 to 18:20

Insights zone 2 (I2)

Oral presentation session

Improving knowledge, protecting health

16:50 to 18:20

Networking zone 3 (N3)

Short communication session

Why we need evidence-based approaches for the universal measurement of cannabis: rationale and implications for public health, treatment and research

16:50 to 18:20

Main stage

Structured session

Thursday, 24 November

10:50

Cannabis use and purchase behaviours in Canada, United States, Australia, and New Zealand: Findings from the International Cannabis Policy Study

10:50 to 12:20

Knowledge market 1 (K1)

Structured session

Substance use and trauma

10:50 to 12:20

Knowledge market 2 (K2)

Oral presentation session

Understanding women's drug use, responses and recovery

10:50 to 12:20

Networking zone 4 (N4)

Short communication session

13:20

Cannabis and tobacco co-use: A ‘joint’ challenge for research and practice

13:20 to 14:50

Knowledge market 1 (K1)

Structured session

Cannabis Social Clubs: current experiences and future directions

13:20 to 14:50

Knowledge market 4 (K4)

Structured session

Childhood risk factors in substance use and mental health

13:20 to 14:50

Knowledge market 2 (K2)

Oral presentation session

Diversity, stigma, and vulnerability

13:20 to 14:50

Networking zone 4 (N4)

Short communication session

15:00

Understanding relationships between substance use, mental health and mental illness: Session 2

15:00 to 16:30

Networking zone 2 (N2)

e-poster guided tour

16:50

New frontiers to regulating cannabis for public health and social justice

16:50 to 18:20

Insights zone 2 (I2)

Oral presentation session

Trajectories of cannabis use during periods of policy change

16:50 to 18:20

Central square 2 (C2)

Oral presentation session

Treatment for cannabis use disorder: an update focusing in cultural characteristics

16:50 to 18:20

Knowledge market 4 (K4)

Structured session

Unpacking the neurobiology of cannabis use disorders and cannabinoids: findings from neuroimaging and experimental studies across different ages and world regions

16:50 to 18:20

Knowledge market 2 (K2)

Structured session

Friday, 25 November

10:50

Associations of alcohol and substance use with mental health

10:50 to 12:20

Knowledge market 2 (K2)

Structured session

Harm reduction or prevention?

10:50 to 12:20

Insights zone 2 (I2)

Oral presentation session

Language values and theory in drugs policy reform

10:50 to 12:20

Knowledge market 1 (K1)

Oral presentation session

13:20

Using innovative data or methods to assess drug markets and drug policy impacts

13:20 to 14:50

Knowledge market 1 (K1)

Oral presentation session

Presentations

Wednesday, 23 November

10:50

Oral presentation

New problems, new approaches: Actions for the case of non-substance addictions for adolescents and young adults

Psychological reactance and adolescent cannabis use: the role of parental warmth and monitoring

Embracing public health approaches to gambling? A review of global legislative and regulatory trends

Attitudes towards alcohol policy in Europe; results of the alcohol survey in 33 European countries

2. Medical use of cannabis and cannabinoids: an overview of evidence

10:50 to 12:20

Knowledge market 4 (K4)

Mafalda Pardal

Oral presentation

5. Treatment of cannabis-related problems in Europe: a typology and evidence overview

10:50 to 12:20

Knowledge market 4 (K4)

Daniel Feingold

Oral presentation

3. Cannabis-related effects and harms: a scientific overview

10:50 to 12:20

Knowledge market 4 (K4)

Jakob Manthey

Oral presentation

4. Harm reduction for cannabis related problems in Europe and beyond

10:50 to 12:20

Knowledge market 4 (K4)

Iciar Indave

Introduction

1. Setting the scene: recent cannabis policy developments in European countries

10:50 to 12:20

Knowledge market 4 (K4)

Liesbeth Vandam

13:20

Oral presentation

5. The U.S. Cannabis Policy Scale: Moving Beyond Dichotomous Measures to Evaluate Impacts of Liberalization Policies on Cannabis and Other Substance Use Outcomes

13:20 to 14:50

Knowledge market 1 (K1)

Rosalie Pacula

Oral presentation

1. Designing a system of monitoring responsible use and distribution of cannabis in Malta

13:20 to 14:50

Knowledge market 1 (K1)

Mariella Dimech

Oral presentation

2. Measuring the impacts of a new cannabis regulation in Luxembourg: the need for valid data collection methods

13:20 to 14:50

Knowledge market 1 (K1)

Nadine Berndt

Oral presentation

3. The Swiss pilot trials with cannabis – evaluation after one year

13:20 to 14:50

Knowledge market 1 (K1)

Maya Ackermann

Oral presentation

4. The Dutch closed cannabis supply chain experiment: background, design of the evaluation study and challenges

13:20 to 14:50

Knowledge market 1 (K1)

Margriet van Laar

Discussion

Adapting monitoring and evaluation to the different versions of 'legalisation', while exploring possible common indicators

13:20 to 14:50

Knowledge market 1 (K1)

Brendan Hughes

Oral presentation

2. Design and Testing of an Aftercare Mobile App for Substance Use Among Young Adults: An Interdisicplinary Approach in Denmark

13:20 to 14:50

Insights zone 2 (I2)

Adriana del Palacio-Gonzalez

Oral presentation

3. A guided digital intervention to reduce cannabis use: the ICan randomized controlled trial in the Netherland

4. Boozebuster: A Mobile Intervention to Promote Low-Risk Drinking Habits in Young Adults –preliminary results

Experiences with and opinions on (sub-)cultural adaptions and other forms of tailoring of digital addiction interventions to meet specific expectations of the target audience.

1. Guided smartphone-based treatment for patients in opioid maintenance treatment in Iran -transdiagnostic treatment for substance use and common mental disorders

4. Estimating the size of the of illicit drug market – a critical review

13:20 to 14:50

Knowledge market 4 (K4)

Robin Udrisard

e-poster

The synthetic cannabinoid ADB-FUBINACA modulates epigenetic mechanisms during in vitro neuronal differentiation at biologically relevant concentrations

13:20 to 14:50

Networking zone 2 (N2)

Felix Carvalho

Oral presentation

5. Estimating the costs of the criminal justice system

13:20 to 14:50

Knowledge market 4 (K4)

Francesco Fabi

e-poster

Profiles of individuals with cannabis-related disorders

13:20 to 14:50

Networking zone 2 (N2)

Marie-Josée Fleury

Discussion

Integrating indicators and estimates

13:20 to 14:50

Knowledge market 4 (K4)

Peter H. Reuter

e-poster

The effects of Synthetic Cannabinoids ADB-FUBINACA, AMB-FUBINACA, AB-CHMINACA and HU-308 on Differentiation and Proliferation of Brain NG108-15 Cells

13:20 to 14:50

Networking zone 2 (N2)

Carolina Freitas

e-poster

Crosstalk between autophagic intermediaries in the event of neurotoxic effects mediated by Synthetic Cannabinoids in NG108-15 cells

13:20 to 14:50

Networking zone 2 (N2)

Catarina Teixeira

e-poster

Treating cannabis use disorder in young adults with text-delivered peer network counseling: A large, multi-site, randomized clinical trial.

13:20 to 14:50

Networking zone 2 (N2)

Michael Mason

e-poster

The arrival of Edibles in Quebec cannabis market : what can be done to minimize the health impact?

13:20 to 14:50

Networking zone 2 (N2)

Julie Loslier

e-poster

What difference will 2.5 grams make? Canada responds to British Columbia’s overdose crisis by agreeing to decriminalize possession of small amounts of drugs

13:20 to 14:50

Networking zone 2 (N2)

Lori Hanson

Oral presentation

1. Drug laws indicators through the leximetric approach and relationship with effectiveness: the example of Italy in the period 1991-2018

13:20 to 14:50

Knowledge market 4 (K4)

Carla Rossi

Oral presentation

2. Hospitalization risk profile of opioids users

13:20 to 14:50

Knowledge market 4 (K4)

Giada Minelli

e-poster

Prevalence and correlates of cannabis use for medicinal reasons – an Australian cross- sectional study

13:20 to 14:50

Networking zone 2 (N2)

Janni Leung

Oral presentation

3. Using Supply Indicators in the Evaluation of Drug Supply Reduction – Challenges and Opportunities

13:20 to 14:50

Knowledge market 4 (K4)

Nicola Singleton

e-poster

Fifth of the inhabitants of Slovenia has already used cannabis or cannabis-derived products for health purposes or is considering it

13:20 to 14:50

Networking zone 2 (N2)

Ada Hocevar Grom

15:00

Short communication

Findings from novel methods of surveillance for fentanyl and novel psychoactive substances within Supervised Injecting Facilities

15:00 to 16:30

Networking zone 4 (N4)

Suzanne Nielsen

Short communication

Detection of Potent 'Nitazene' Synthetic Opioids by a networked drug checking service in Toronto, Ontario, Canada

15:00 to 16:30

Networking zone 4 (N4)

Kristy Scarfone

Short communication

Access to medical cannabis in Brazil: informal regulation via patient associations as a social movement

15:00 to 16:30

Networking zone 4 (N4)

Paulo J. R. Pereira

Short communication

Method development for monitoring Google-indexed e-shops offering new psychoactive substances (NPS) in The Netherlands.

15:00 to 16:30

Networking zone 4 (N4)

Lavinia Stegemann

Short communication

How to evaluate complex drug policies? A case study of the Belgian drug policy

15:00 to 16:30

Networking zone 4 (N4)

Eva Blomme

Short communication

The Unit of Cannabis: from a systematic review to a NIDA recommendation

15:00 to 16:30

Networking zone 4 (N4)

María Teresa Pons-cabrera

Short communication

A longitudinal study of a drug checking service for patrons of Boom Festival 2018: behavioral outcomes at individual and group levels.

15:00 to 16:30

Networking zone 4 (N4)

Helena Valente

Short communication

Using Reddit Social Media Data to Uncover Self-medication and Drug Use Trends among Opioid Users: Semi-automated Natural Language Processing Approach.

15:00 to 16:30

Networking zone 4 (N4)

Georgiy Bobashev

e-poster

Association of the 2016 UK Psychoactive Substance Act with hospital presentations following analytically confirmed synthetic cannabinoid receptor agonist exposure.

15:00 to 16:30

Networking zone 1 (N1)

Sam Craft

e-poster

Is there a long-term relationship between cannabis and heroin use? An 18-20-year follow-up of the Australian Treatment Outcome Study (ATOS)

15:00 to 16:30

Networking zone 1 (N1)

Jack Wilson

e-poster

Do Medical Cannabidiol Laws Reduce Nonfatal and Fatal Opioid Overdose Rates?

15:00 to 16:30

Networking zone 1 (N1)

Rahi Abouk

e-poster

Regulating cannabis : a comparative perspective on policy rollouts and unintended consequences in The United States and Canada (lessons from 6 case studies)

15:00 to 16:30

Networking zone 1 (N1)

Ivana Obradovic

e-poster

The Effects of Recreational Cannabis Laws on Pharmacy- and Hospital-Based Opioid Distribution in the United States

15:00 to 16:30

Networking zone 1 (N1)

Coleman Drake

16:50

Oral presentation

Integrating the Notions of Complexity and Social Suffering to Provide Better Care to Sexually and Gender-Diverse Men Who Use Methamphetamine

Sustaining non-use of party drugs among Dutch young adults

Why do young people use cannabis – or decide not to?

16:50 to 18:20

Insights zone 2 (I2)

Anne Line Bretteville-Jensen

Oral presentation

LEt’s Talk about drugs: Assessment of drug education in Bulgaria, Hungary, Lithuania, Poland, and Serbia

1. The standard THC unit

2. Paving the Way for Improved Data Collection on Cannabis Use

3. The International Cannabis Toolkit (iCannToolkit): a first necessary step to integrate global multidisciplinary evidence on cannabis related risks and benefits

4. From standard drinks to the cannabis toolkit

2. Epidemiological studies on cannabis and crash risk

3. Toxicology: detection of THC impairment

4. Policy and legislation

5. Medical use and novel cannabinoids

1. Experimental studies on cannabis and driving impairment

In vitro toxicity of the synthetic cannabinoids THJ-2201 and ADB-FUBINACA to human astrocytes

16:50 to 18:20

Networking zone 3 (N3)

Rafaela Silva

Short communication

Virtual Opioid User: Simulating the Effects of Counterfeit Pill Prevalence with a Control Theory Model

16:50 to 18:20

Networking zone 3 (N3)

Alexander Preiss

Short communication

The Influence of the Synthetic Cannabinoids AMB-FUBINACA, ADB-FUBINACA, AB-CHMINACA and THJ-2201 on In Vitro Viability and Senescence of SH-SY5Y Cells and Primary Rat Hippocampal Neurons

16:50 to 18:20

Networking zone 3 (N3)

Rita Roque Bravo

Short communication

Organ pathologies detected post-mortem in patients receiving opioid agonist treatment for opioid use disorder: a nationwide 2-year cross-sectional study

16:50 to 18:20

Networking zone 3 (N3)

Anne Berit Bech

Short communication

Successful microelimination of HCV among patients in the Romanian prison system

16:50 to 18:20

Networking zone 3 (N3)

Adrian Abagiu

Short communication

The synthetic cannabinoids ADB-FUBINACA and THJ-2201 decrease mitochondrial activity and ATP levels during neurodifferentiation of NG108-15 cells

16:50 to 18:20

Networking zone 3 (N3)

Rui Filipe Malheiro

Short communication

Impact of the COVID-19 pandemic on drug use in the Republic of North Macedonia

16:50 to 18:20

Networking zone 3 (N3)

Sanja Prosheva

Short communication

Non-pharmacological treatment interventions in UK drug and alcohol services: an exploratory study

16:50 to 18:20

Networking zone 3 (N3)

Karen Megranahan

Thursday, 24 November

10:50

Oral presentation

addictive disorders and post-traumatic stress disorders

10:50 to 12:20

Knowledge market 2 (K2)

Léa Montagnier

Oral presentation

A novel trauma-focused psychological therapy for co-occurring substance use and PTSD among adolescents

10:50 to 12:20

Knowledge market 2 (K2)

Emma Barrett

Oral presentation

The association between moral injury and cannabis use disorder among Israeli combat veterans: current state of knowledge and future directions

10:50 to 12:20

Knowledge market 2 (K2)

Daniel Feingold

Oral presentation

Alcohol and drug use among trauma patients with injuries of violence– results from the IDART study

10:50 to 12:20

Knowledge market 2 (K2)

Benedicte Jørgenrud

Oral presentation

1. The International Cannabis Policy Study – Framework for evaluating cannabis legalization

10:50 to 12:20

Knowledge market 1 (K1)

David Hammond

Oral presentation

2. Patterns of problematic cannabis use among Canadian and US respondents between 2018 and 2020: Findings from the International Cannabis Policy Study

10:50 to 12:20

Knowledge market 1 (K1)

Cesar Leos-Toro

Oral presentation

3. Perceptions of illegal and legal cannabis in Canada in the three years after cannabis legalization: Findings from the International Cannabis Policy Study

10:50 to 12:20

Knowledge market 1 (K1)

TBD TBD

Short communication

Gender differences in cannabis use disorder symptoms: A network analysis

10:50 to 12:20

Networking zone 4 (N4)

Emese Kroon

Short communication

Photovoicing interconnected sources of recovery capital of women with a drug use history

10:50 to 12:20

Networking zone 4 (N4)

Jessica De Maeyer

Short communication

Complex social and health care needs of women who seek addiction treatment: listening to their voices to guide long-term integrated services that take into account gender

10:50 to 12:20

Networking zone 4 (N4)

Karine Bertrand

Short communication

Mutual help groups for women who use drugs, as a community-led gender sensitive harm reduction response

10:50 to 12:20

Networking zone 4 (N4)

Lígia Parodi

Short communication

Exploring intersections between gender and drug use in East and Southern Africa

10:50 to 12:20

Networking zone 4 (N4)

Charity Monareng

Short communication

Mutual support groups among women who use drugs in a community context as a comprehensive and affordable strategy to reduce inequalities

10:50 to 12:20

Networking zone 4 (N4)

Joana Canedo

13:20

Short communication

Perceptions of prospective pharmaceutical stimulant substitution treatments among people who use illicit stimulants in Vancouver, Canada

13:20 to 14:50

Networking zone 4 (N4)

Taylor Fleming

Short communication

Trends and factors associated with illicit drug use and HIV outcomes in South Africa: findings from multiple national population-based household surveys

13:20 to 14:50

Networking zone 4 (N4)

Kennedy Kipkoech

Short communication

Perceived Impact of Storytelling on Substance Use Self-Stigma

13:20 to 14:50

Networking zone 4 (N4)

Glenn Sterner

Short communication

Social attitudes towards drug users in the context of perceptions of other marginalised social groups, based on the NSAPH 2019 Survey

13:20 to 14:50

Networking zone 4 (N4)

Katalin Felvinczi

Short communication

Cannabis engagement in Riga, Latvia: Voices from impacted communities

13:20 to 14:50

Networking zone 4 (N4)

Kristiana Bebre

Short communication

SHIFT + Parent Training - An Intervention for Mothers and Fathers Using Illicit Drugs'

13:20 to 14:50

Networking zone 4 (N4)

Diana Moesgen

Oral presentation

The Role of Adverse Childhood Experiences (ACEs) on People in Opiate Agonist Treatment: The importance of feeling unloved

13:20 to 14:50

Knowledge market 2 (K2)

David McDonagh

Oral presentation

Longitudinal patterns of problematic cannabis use in adolescence and their association with childhood psychological risk factors

13:20 to 14:50

Knowledge market 2 (K2)

Rachel Lees

Oral presentation

Childhood maltreatment and alcohol problems in young adulthood: coping style as a mediator and potential intervention target.

13:20 to 14:50

Knowledge market 2 (K2)

Lucinda Grummitt

Oral presentation

Exploring the link between childhood maltreatment and substance use disorder using a prospective, genetically informative and experimental approach

13:20 to 14:50

Knowledge market 2 (K2)

Andrea Johansson Capusan

Oral presentation

1. Cannabis Social Clubs in Europe: a transnational social movement network in the making?

13:20 to 14:50

Knowledge market 4 (K4)

Melissa Bone

Oral presentation

3. Legal or not: a comparative analysis of Belgian and Uruguayan CSC members’ profile and policy preferences

13:20 to 14:50

Knowledge market 4 (K4)

Lorena Repetto

Oral presentation

4. Drug social clubs – the next social club generation?

13:20 to 14:50

Knowledge market 4 (K4)

Chris Wilkins

Oral presentation

3. The Cannabis And Tobacco Cessation Advice (CATCA) project: A mixed method study exploring UK stop smoking practitioners’ knowledge, attitudes and practices around co-use

13:20 to 14:50

Knowledge market 1 (K1)

Maria Duaso

Oral presentation

4. Changes in tobacco use among people with cannabis use disorder treated in programs

13:20 to 14:50

Knowledge market 1 (K1)

Cristina Martínez

Oral presentation

2. Quitting experiences, attitudes and beliefs amongst UK young adult co-smokers: A qualitative interview study

13:20 to 14:50

Knowledge market 1 (K1)

Hannah Walsh

Oral presentation

1. Association of cannabis and tobacco use with incident anxiety, mood and psychotic disorders: a systematic review

13:20 to 14:50

Knowledge market 1 (K1)

Chloe Burke

Short communication

Under-reporting of meth/amphetamine use in Australia following negative media coverage

13:20 to 14:50

Networking zone 4 (N4)

Daniel Stjepanovic

Short communication

Treatment of drug use disorders in Central Asia, China, and Germany – what is the state of the art?

13:20 to 14:50

Networking zone 4 (N4)

Ingo Ilja Michels

Oral presentation

2. What are the barriers and prospects for establishing Cannabis Social Clubs in New Zealand?

13:20 to 14:50

Knowledge market 4 (K4)

Marta Rychert

15:00

e-poster

The war on time: an insight into the temporal relation between cannabis consumption and toxic psychosis

15:00 to 16:30

Networking zone 2 (N2)

Ana Soares

e-poster

Smoking-related health inequalities, tobacco smoking and substance use disorder.

15:00 to 16:30

Networking zone 2 (N2)

Mireia Graell Gabriel

e-poster

Program 'Eu e os Outros': Adaptation to the university context

15:00 to 16:30

Networking zone 2 (N2)

Mariana Montalvão

e-poster

Perception of the risk associated with drug use in patients with a previous episode of Cannabis-Induced Psychotic Disorder

15:00 to 16:30

Networking zone 2 (N2)

Maria Coelho

e-poster

Khat and neurobehavioral functions: a systematic review

15:00 to 16:30

Networking zone 2 (N2)

Manuel Jesús Ruiz Muñoz

e-poster

Group Intervention for Parents of People With Psychotic and Substance Use Disorders: A Qualitative Evaluation of appropriateness

15:00 to 16:30

Networking zone 2 (N2)

Karine Gaudreault

e-poster

How Attention Deficit Hyperactivity Disorder and Substance Use Disorder influence each other: A non-systematic literature review

15:00 to 16:30

Networking zone 2 (N2)

Catarina Oliveira

e-poster

Antisocial personality disorder: A high risk of polydrug use?

15:00 to 16:30

Networking zone 2 (N2)

Ayoub Salhi

e-poster

Prescription Patterns on Patients with Dual Diagnosis: A Retrospective Inpatient Analysis

15:00 to 16:30

Networking zone 2 (N2)

Inês Pereira

e-poster

Substance-Related Problems in Adolescents with ADHD-Diagnoses: The Importance of Self-Reported Conduct Problems

15:00 to 16:30

Networking zone 2 (N2)

Ove Heradstveit

e-poster

The Clinical Course of Comorbid Substance Use Disorder and Attention Deficit/Hyperactivity Disorder: Protocol and Clinical Characteristics of the INCAS Study

15:00 to 16:30

Networking zone 2 (N2)

Johan Franck

16:50

Oral presentation

Equity in Marijuana Policies: A Comparative Study of two U.S. States using Critical Race Theory.

Differences in cannabis use and opinions on drug policy between generations

16:50 to 18:20

Central square 2 (C2)

Pekka Hakkarainen

Oral presentation

Adolescent cannabis use during a period of rapid policy change: Evidence from the US PATH Study

16:50 to 18:20

Central square 2 (C2)

Mike Vuolo

Oral presentation

The role played by evidence on the effects of cannabis use in cannabis policy 1992-2022

16:50 to 18:20

Central square 2 (C2)

Eva Hoch

Oral presentation

Trajectories of Prescribed Medical Cannabis Filled Over Time

16:50 to 18:20

Central square 2 (C2)

Alexandra Kritikos

Oral presentation

Medical cannabis regulation: Taking the best of the North American and European models

Municipal variations in cannabis regulation regarding public consumption and retail sales in Canada

Québec's public, not-for-profit cannabis distribution regime: a comparative analysis, three years in

Regulating Cannabis for Public Health

Mitigating the risks of corporate capture in emerging legal cannabis markets

1. Cannabis use disorder and the brain: What’s culture got to do with it?

16:50 to 18:20

Knowledge market 2 (K2)

Janna Cousijn

Oral presentation

2. Resting state functional connectivity of the dorsal attention network in cannabis use disorder: a fMRI study

16:50 to 18:20

Knowledge market 2 (K2)

Lisa-Marie Greenwood

Oral presentation

3. Brain reward function in young people with a dsm-5 diagnosis of Cannabis Use Disorder: a fMRI study

16:50 to 18:20

Knowledge market 2 (K2)

Valentina Lorenzetti

Oral presentation

4. Neural response to reward anticipation after acute exposure to cannabis with and without cannabidiol in adults and adolescents

16:50 to 18:20

Knowledge market 2 (K2)

Martine Skumlien

Oral presentation

5. Acute effects of four CBD:THC ratios on attentional bias to cannabis and food cues: a randomized, double-blind, crossover study

16:50 to 18:20

Knowledge market 2 (K2)

Dominic Oliver

Oral presentation

2. Motivational Interviewing for CUD: current situation and gaps

16:50 to 18:20

Knowledge market 4 (K4)

Hugo López Pelayo

Oral presentation

3. Cultural and language adaptation to Spanish of CANnabis DISorder Program (CANDIS)

16:50 to 18:20

Knowledge market 4 (K4)

Pablo Guzmán

Oral presentation

4. Pros and Cons of Group Therapy for Cannabis Use Disorders: Is it an opportunity for cultural adaptation?

16:50 to 18:20

Knowledge market 4 (K4)

Mercè Balcells

Oral presentation

1. Pharmacological treatments for cannabis use disorder

16:50 to 18:20

Knowledge market 4 (K4)

Albert Batalla

Friday, 25 November

10:50

Oral presentation

What would it take to get people to stop rolling joints with tobacco?

Personas in drug use - Understanding substance-use motives in young adults

Data mining-based profiles of emerging adults at elevated risk for negative alcohol use consequences

Strategic Ignorance or Counter Knowledge: 60 years of Harm Reduction Debates in Swedish Parliament

1. Socioeconomic status, alcohol use and the mediating role of social support and neighbourhood disadvantage among individuals meeting criteria for a mental health problem: a cross-sectional study

10:50 to 12:20

Knowledge market 2 (K2)

Jo-Anne Puddephatt

Oral presentation

2. The association between mental health and alcohol use in racial and ethnic groups: A secondary data analysis across studies

10:50 to 12:20

Knowledge market 2 (K2)

Laura Goodwin

Oral presentation

3. Association of psychological distress with smoking cessation, duration of smoking abstinence and use of other nicotine-containing products: A cross-sectional population survey in Great Britain

10:50 to 12:20

Knowledge market 2 (K2)

Leonie Brose

Oral presentation

4. Can we make cannabis safer? An experimental study of four CBD: THC rations in healthy volunteers

10:50 to 12:20

Knowledge market 2 (K2)

Amir Englund

Oral presentation

Why did New Zealand’s referendum to legalise recreation cannabis fail? An analysis of media campaigns and predictors of voter support for cannabis legalisation in New Zealand

10:50 to 12:20

Knowledge market 1 (K1)

Marta Rychert

Oral presentation

Language matters and it starts with us: How to talk about drugs to advocate for reform more effectively

10:50 to 12:20

Knowledge market 1 (K1)

Alice Salomon

Oral presentation

The Policy Constellation Approach: application of a critical realist public policy theory to the explanation of the UK’s drug strategy for 2021-2031

10:50 to 12:20

Knowledge market 1 (K1)

Alex Stevens

Oral presentation

The utility of different values frameworks for drug policy analysis

10:50 to 12:20

Knowledge market 1 (K1)

Alison Ritter

Discussion

Commonalities across the research on different substances

10:50 to 12:20

Knowledge market 2 (K2)

Abi Rose

13:20

Oral presentation

Cannabis regulation and fiscal policy: Opportunities for human rights in Colombia

13:20 to 14:50

Knowledge market 1 (K1)

Luis Felipe Cruz-olivera

Oral presentation

Prioritising measures to assess performance of drug treatment services: perspectives of funders, treatment providers and service users

13:20 to 14:50

Knowledge market 1 (K1)

Robert Stirling

Oral presentation

Tracking the illicit Cannabis Market during the closed Cannabis Supply Chain Experiment in Netherlands using an online Crowdsourcing Approach

13:20 to 14:50

Knowledge market 1 (K1)

Stijn Hoorens

Oral presentation

Triangulating wastewater and a prospective survey of drug consumption – new insights for policy makers

13:20 to 14:50

Knowledge market 1 (K1)

Caitlin Hughes

Oral presentation

The effects of cannabis liberalization laws on health, safety, and socioeconomic outcomes: An evidence and gap map

13:20 to 14:50

Knowledge market 1 (K1)

Eric Sevigny